NCT01405339View on ClinicalTrials.gov

Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

January 31, 2014

Conditions
Chronic Rhinosinusitis
Interventions
DEVICE

Mucosal Atomization Device (MAD)

The use of pulmicort via MAD once a day for a total of 30 days.

DEVICE

Budesonide via Nasal Syringe

The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.

Trial Locations (1)

V6Z 1Y6

ENT Clinic, St. Paul's Hospital, Vancouver

All Listed Sponsors
lead

St. Paul's Hospital, Canada

OTHER

NCT01405339 - Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray | Biotech Hunter | Biotech Hunter